Skip to main content
. 2022 Jul 28;108(1):290–294. doi: 10.3324/haematol.2022.281351

Figure 1.

Figure 1.

Positron emission tomography/computerized tomography scan and bone marrow examination before and afer chimeric antigen receptor T-cell infusion. (A and B) Positron emission tomography/computerized tomography (FDG-PET/CT) scan coronal maximum intensity projection (MIP) images before leukapheresis with avid uptake of abdominal lymph nodes (A) and 3 months after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (B), showing metabolic complete response of diffuse large B-cell lymphoma (DLBCL). (C) Bone marrow (BM) biopsy taken before CAR T-cell infusion showing an hypocellular marrow without leukemic infiltration (hematoxylin and eosin staining; magnification x400). (D) The same sample as (C) showing only rare CD34+ cells within the normal range (red arrow); vessel endothelial cells serve as positive control (black arrow) (immunoperoxidase, diaminobenzidine; magnification x200). (E) BM biopsy taken 2 months after CAR T-cell infusion showing hypocellular marrow infiltrated by CD34+ leukemic cells (red arrows); vessel endothelial cells serve as positive control (black arrows) (immunoperoxi-dase, diaminobenzidine; magnification x200). (F) BM smear 2 months after CAR T-cell infusion showing myeloid blasts exhibiting erythrophagocytosis (black arrows) (May-Grunwald-Giemsa staining, magnification x400).